
NGNE
Healthcare · Biotechnology · $495.4M market cap
$23.93+0.03 (+0.1%)Nov 13, 4:05 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -4.5% over 90 days · 30-day revisions 3 up, 3 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 9, 2026 | After the close | -1.49 | -1.05 | +29.5% |
| Aug 11, 2026 | After the close | -1.40 | -1.53 | -9.3% |
| May 13, 2026 | Time not confirmed | -1.27 | -1.39 | -9.1% |
| Mar 24, 2026 | After the close | -1.24 | -1.13 | +8.9% |
| Nov 13, 2025 | After the close | -1.09 | -0.99 | +9.2% |
| Aug 11, 2025 | After the close | -1.16 | -1.05 | +9.5% |
| May 8, 2025 | Before the open | -1.12 | -1.08 | +3.6% |
| Mar 24, 2025 | After the close | -1.13 | -0.99 | +12.4% |
| Nov 18, 2024 | After the close | -1.22 | -1.19 | +2.5% |
| Aug 9, 2024 | Before the open | -1.03 | -1.09 | -5.8% |
| May 10, 2024 | After the close | -0.95 | -1.00 | -5.3% |
| Mar 18, 2024 | After the close | -1.17 | -1.51 | -29.1% |
| Nov 14, 2023 | Time not confirmed | -0.03 |
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a…
| -0.41 |
| -1259.0% |
| Aug 16, 2023 | Time not confirmed | -0.04 | -0.04 | 0.0% |
| May 10, 2023 | Time not confirmed | -0.22 | -0.26 | -18.2% |
| Mar 16, 2023 | Time not confirmed | -0.19 | -0.24 | -26.3% |
| Nov 14, 2022 | Time not confirmed | -0.30 | -0.24 | +21.1% |
| Aug 9, 2022 | Time not confirmed | -0.30 | -0.28 | +6.7% |
| May 9, 2022 | Time not confirmed | -0.30 | -0.28 | +6.0% |
| Mar 1, 2022 | Time not confirmed | -0.30 | -0.28 | +5.3% |
| Nov 4, 2021 | Time not confirmed | -0.28 | -0.28 | -0.6% |
| Aug 5, 2021 | Time not confirmed | -0.26 | -0.27 | -3.1% |
| May 12, 2021 | Time not confirmed | -0.23 | -0.27 | -18.4% |
| Mar 25, 2021 | Time not confirmed | -0.24 | -0.22 | +9.9% |
| Nov 9, 2020 | Time not confirmed | -0.22 | -0.04 | +81.8% |
| Aug 12, 2020 | Time not confirmed | -0.21 | -0.20 | +4.8% |
| May 6, 2020 | Time not confirmed | -0.23 | -0.18 | +21.7% |
| Mar 12, 2020 | Time not confirmed | -0.28 | -0.23 | +17.9% |
| Nov 13, 2019 | Time not confirmed | -0.04 | -2.26 | -5550.0% |
| Aug 7, 2019 | Time not confirmed | -0.05 | -0.09 | -80.0% |
| May 6, 2019 | Time not confirmed | -0.23 | -0.09 | +60.9% |
| Mar 18, 2019 | Time not confirmed | -0.79 | -0.21 | +73.4% |
| Nov 7, 2018 | Time not confirmed | -0.21 | -0.64 | -204.8% |
| Aug 8, 2018 | Time not confirmed | -0.59 | 0.12 | +120.3% |
| May 8, 2018 | Time not confirmed | -0.66 | -0.62 | +6.1% |
| Mar 12, 2018 | Time not confirmed | -0.57 | -0.69 | -21.1% |